SOX9 drives WNT pathway activation in prostate cancer

Journal of Clinical Investigation

Volumn 126, Issue 5, 2016, Pages 1745-1758

  Ma, Fen ^a   Ye, Huihui ^a   He, Housheng Hansen ^b,c   Gerrin, Sean J ^a   Chen, Sen ^a   Tanenbaum, Benjamin A ^a   Cai, Changmeng ^a   Sowalsky, Adam G ^a   He, Lingfeng ^a   Wang, Hongyun ^a   Balk, Steven P ^a   Yuan, Xin ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; FRIZZLED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROTEIN SYNTHESIS INHIBITOR; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTOME; WNT PROTEIN; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; LGK974; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SOX9 PROTEIN, HUMAN; TCF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; GENE CONTROL; GENETIC CODE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SCID MOUSE; TUMOR CELL LINE; WNT SIGNALING;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PYRAZINES; PYRIDINES; SOX9 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988535650     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78815     Document Type: Article

References (75)

1. Foster JW, et al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRYrelated gene. Nature. 1994;372(6506):525-530.
2. Wagner T, et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell. 1994;79(6):1111-1120.
3. Blache P, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol. 2004;166(1):37-47.
4. Lincoln J, Kist R, Scherer G, Yutzey KE. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol. 2007;305(1):120-132.
5. Seymour PA, et al. SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proc Natl Acad Sci U S A. 2007;104(6):1865-1870.
6. Vidal VP, et al. Sox9 is essential for outer root sheath differentiation and the formation of the hair stem cell compartment. Curr Biol. 2005;15(15):1340-1351.
7. Furuyama K, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet. 2011;43(1):34-41.
8. Lu B, et al. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol. 2008;130(6):897-904.
9. Kopp JL, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22(6):737-750.
10. Huang Z, et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget. 2012;3(6):651-663.
11. Thomsen MK, et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010;70(3):979-987.
12. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res. 2007;67(2):528-536.
13. Wang H, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008;68(6):1625-1630.
14. Thomsen MK, Butler CM, Shen MM, Swain A. Sox9 is required for prostate development. Dev Biol. 2008;316(2):302-311.
15. Schaeffer EM, et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008;27(57):7180-7191.
16. Acevedo VD, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12(6):559-571.
17. Zhang X, Cowper-Sal lari R, Bailey SD, Moore JH, Lupien M. Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus. Genome Res. 2012;22(8):1437-1446.
18. Cai C, et al. ERG induces androgen receptormediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013;123(3):1109-1122.
19. Tomlins SA, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008;10(2):177-188.
20. Chen Y, et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med. 2013;19(8):1023-1029.
21. Yu J, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010;17(5):443-454.
22. Huang W, Zhou X, Lefebvre V, de Crombrugghe B. Phosphorylation of SOX9 by cyclic AMPdependent protein kinase A enhances SOX9's ability to transactivate a Col2a1 chondrocyte-specific enhancer. Mol Cell Biol. 2000;20(11):4149-4158.
23. Mertin S, McDowall SG, Harley VR. The DNA-binding specificity of SOX9 and other SOX proteins. Nucleic Acids Res. 1999;27(5):1359-1364.
24. Oh CD, et al. Identification of SOX9 interaction sites in the genome of chondrocytes. PLoS One. 2010;5(4):e10113.
25. Bhandari RK, Haque MM, Skinner MK. Global genome analysis of the downstream binding targets of testis determining factor SRY and SOX9. PLoS One. 2012;7(9):e43380.
26. Kadaja M, et al. SOX9: a stem cell transcriptional regulator of secreted niche signaling factors. Genes Dev. 2014;28(4):328-341.
27. Wang G, et al. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet. 2013;45(7):739-746.
28. Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
29. Haller R, et al. Notch1 signaling regulates chondrogenic lineage determination through Sox9 activation. Cell Death Differ. 2012;19(3):461-469.
30. Martini S, et al. A critical role for Sox9 in notch-induced astrogliogenesis and stem cell maintenance. Stem Cells. 2013;31(4):741-751.
31. Shih HP, et al. A Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell differentiation. Development. 2012;139(14):2488-2499.
32. van Leenders GJ, et al. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One. 2011;6(11):e26753.
33. Blache P, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol. 2004;166(1):37-47.
34. Kruithof-de Julio M, et al. Canonical Wnt signaling regulates Nkx3.1 expression and luminal epithelial differentiation during prostate organogenesis. Dev Dyn. 2013;242(10):1160-1171.
35. Gupta S, et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelialto-mesenchymal transition in human prostate cancer cells. Cancer Res. 2010;70(17):6735-6745.
36. Wu L, Zhao JC, Kim J, Jin HJ, Wang CY, Yu J. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res. 2013;73(19):6068-6079.
37. Wang H, et al. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/ β-catenin activation in breast cancer. J Biol Chem. 2013;288(9):6478-6487.
38. Camargo FD, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17(23):2054-2060.
39. Rosenbluh J, et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457-1473.
40. Minami Y, Oishi I, Endo M, Nishita M. Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev Dyn. 2010;239(1):1-15.
41. Green J, Nusse R, van Amerongen R. The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction. Cold Spring Harb Perspect Biol. 2013;6(2):a009175.
42. Ho HY, et al. Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci U S A. 2012;109(11):4044-4051.
43. Verhaegh W, et al. Selection of personalized patient therapy through the use of knowledgebased computational models that identify tumordriving signal transduction pathways. Cancer Res. 2014;74(11):2936-2945.
44. Liu J, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013;110(50):20224-20229.
45. Lepourcelet M, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004;5(1):91-102.
46. Krieghoff E, Behrens J, Mayr B. Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention. J Cell Sci. 2006;119(pt 7):1453-1463.
47. Placencio VR, et al. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res. 2008;68(12):4709-4718.
48. Li X, et al. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene. 2008;27(56):7118-7130.
49. Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009;19(6):683-697.
50. Pearson HB, Phesse TJ, Clarke AR. K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res. 2009;69(1):94-101.
51. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene. 2011;30(16):1868-1879.
52. Zong Y, et al. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci U S A. 2012;109(50):E3395-E3404.
53. Francis JC, Thomsen MK, Taketo MM, Swain A. β-Catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet. 2013;9(1):e1003180.
54. Carstens JL, et al. FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014;74(2):609-620.
55. Kypta RM, Waxman J. Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9(8):418-428.
56. Bismar TA, Humphrey PA, Grignon DJ, Wang HL. Expression of β-catenin in prostatic adenocarcinomas: a comparison with colorectal adenocarcinomas. Am J Clin Pathol. 2004;121(4):557-563.
57. de la Taille A, et al. Beta-catenin-related anomalies in apoptosis-resistant and hormonerefractory prostate cancer cells. Clin Cancer Res. 2003;9(5):1801-1807.
58. Horvath LG, et al. Lower levels of nuclear β-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer. 2005;113(3):415-422.
59. Kallakury BV, et al. Decreased expression of catenins (α and β), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer. 2001;92(11):2786-2795.
60. Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. Alterations in β-catenin expression and localization in prostate cancer. Prostate. 2008;68(11):1196-1205.
61. Truica CI, Byers S, Gelmann EP. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 2000;60(17):4709-4713.
62. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a means for inhibition of the Tcf signaling axis. Oncogene. 2003;22(36):5602-5613.
63. Yang F, et al. Linking β-catenin to androgen-signaling pathway. J Biol Chem. 2002;277(13):11336-11344.
64. Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP. A direct β-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem. 2003;278(33):30828-30834.
65. Lee E, Madar A, David G, Garabedian MJ, Dasgupta R, Logan SK. Inhibition of androgen receptor and β-catenin activity in prostate cancer. Proc Natl Acad Sci U S A. 2013;110(39):15710-15715.
66. Nguyen LT, et al. ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors. Cancer Cell. 2015;27(6):797-808.
67. Sun Y, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18(9):1359-1368.
68. Akiyama H, et al. Interactions between Sox9 and β-catenin control chondrocyte differentiation. Genes Dev. 2004;18(9):1072-1087.
69. Topol L, Chen W, Song H, Day TF, Yang Y. Sox9 inhibits Wnt signaling by promoting β-catenin phosphorylation in the nucleus. J Biol Chem. 2009;284(5):3323-3333.
70. Aryee MJ, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 2013;5(169):169ra10.
71. Chen Y, et al. APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. Eur J Hum Genet. 2013;21(9):929-935.
72. Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-1228.
73. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
74. Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137.
75. Liu T, et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011;12(8):R83.